Kara Marlatt, PhD
DirectorAs a member of Sg2’s Intelligence team, Kara contributes to the development and delivery of Sg2’s oncology intelligence by evaluating the impact of emerging trends, therapeutics and technologies on care delivery. To aid these efforts, Kara contributes to publications, member meetings and educational events, and Sg2’s rich data capabilities via our Impact of Change® forecast and use of Vizient® data analytics with the goal of helping health systems and service line leaders best position themselves for the future.
Prior to joining Sg2, Kara worked at The Advisory Board Company where she specialized in service line growth strategies (including oncology, obesity and diabetes, and women’s health), value-based care, and consumer strategy. In this role, she was a frequent speaker at health system retreats, board meetings, and Summit and roundtable events surrounding these strategies. Before that, Kara was an NIH-funded clinical researcher at the Pennington Biomedical Research Center, a world-renowned research institute at the forefront of obesity, diabetes, cancer and women’s health research. Her collective research focused on how weight (adiposity) changes and cancer therapeutics alter cardiometabolic health, resulting in more than 50 peer-reviewed publications and presentations at many scientific meetings. She also worked in the proton therapy industry and was an analyst at a middle-market investment bank in the health care M&A division.
Kara earned her PhD in physiology and MPH in epidemiology from the University of Minnesota-Twin Cities, where she studied the impact of cancer therapeutics on cardiovascular risk. She also has an MS in clinical research from Tulane University and a BA in health care economics from Carleton College.
Prior to joining Sg2, Kara worked at The Advisory Board Company where she specialized in service line growth strategies (including oncology, obesity and diabetes, and women’s health), value-based care, and consumer strategy. In this role, she was a frequent speaker at health system retreats, board meetings, and Summit and roundtable events surrounding these strategies. Before that, Kara was an NIH-funded clinical researcher at the Pennington Biomedical Research Center, a world-renowned research institute at the forefront of obesity, diabetes, cancer and women’s health research. Her collective research focused on how weight (adiposity) changes and cancer therapeutics alter cardiometabolic health, resulting in more than 50 peer-reviewed publications and presentations at many scientific meetings. She also worked in the proton therapy industry and was an analyst at a middle-market investment bank in the health care M&A division.
Kara earned her PhD in physiology and MPH in epidemiology from the University of Minnesota-Twin Cities, where she studied the impact of cancer therapeutics on cardiovascular risk. She also has an MS in clinical research from Tulane University and a BA in health care economics from Carleton College.